Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2015 May;13(5):527-30.
doi: 10.1586/14787210.2015.1028368. Epub 2015 Mar 23.

A long-lasting, single-dose nasal vaccine for Ebola: a practical armament for an outbreak with significant global impact

Kristina Jonsson-Schmunk  1 , Maria A Croyle
Affiliations
Editorial

A long-lasting, single-dose nasal vaccine for Ebola: a practical armament for an outbreak with significant global impact

Kristina Jonsson-Schmunk et al. Expert Rev Anti Infect Ther. 2015 May.

Abstract

In response to the severity and scale of the 2014 Ebola outbreak, several experimental vaccines were granted fast-track status for clinical testing. Although they may provide long-lasting protection from Ebola, they are, in their current states, far from optimal for populations that need them the most. In this context, nasal immunization addresses the: immune response required at the mucosa where Ebola initiates infection; needs of a population in terms of cost and compliance; and potency of each platform as they contain viruses that naturally infect the respiratory tract. Understanding the attributes of nasal immunization and its application will lead to potent vaccines that can effectively end Ebola and other emerging infectious diseases in developing and industrialized countries.

Keywords: Ebola; VSV; adenovirus; clinical trial; developing country; formulation; nasal vaccine.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Marí Saéz A, Weiss S, Nowak K, Lapeyre V, Zimmermann F, Düx A, Kühl HS, et al. Investigating the Zoonotic Origin of the West African Ebola Epidemic. EMBO Mol. Med. 2014;7(1):17–23. - PMC - PubMed
    1. Maurice J. WHO Meeting Chooses Untried Interventions to Defeat Ebola. Lancet. 2014;384(9948):e45–e46. - PubMed
    1. Stanley DA, Honko AN, Asiedu C, Trefry JC, Lau-Kilby AW, Johnson JC, Hensley L, et al. Chimpanzee Adenovirus Vaccine Generates Acute and Durable Protective Immunity Against Ebolavirus Challenge. Nat. Med. 2014;20(10):1126–1129. [One of the first studies to demonstrate long lasting protection from lethal Ebola infection with a cAd3 vector based vaccine in primates.] - PubMed
    1. Ledgerwood JE, DeZure AD, Stanley DA, Novik L, Enama ME, Berkowitz NM, Hu Z, et al. Chimpanzee Adenovirus Vector Ebola Vaccine - Preliminary Report. N. Engl. J. Med. [ePub ahead of print (Nov. 26, 2014). The first report of results from a Phase I human clinical trial on a fast track Ebola vaccine during the 2014 outbreak.] - PubMed
    1. Rampling T, Ewer K, Bowyer G, Wright D, Imoukhuede EB, Payne R, Hartnell F, et al. A Monovalent Chimpanzee Adenovirus Ebola Vaccine - Preliminary Report. N. Engl. J. Med. [ePub ahead of print (Jan 28, 2015). The second report of results the largest to date Phase I human clinical trial on a fast track Ebola vaccine during the 2014 outbreak.] - PMC - PubMed

Publication types

MeSH terms